Rain Therapeutics to Report Third Quarter 2021 Financial Results and Highlights of Recent Progress on November 10, 2021
Rain Therapeutics Inc. (NasdaqGS: RAIN) is set to report its Q3 financial results for the period ending September 30, 2021, on November 10, 2021. The company will also highlight recent advancements in precision oncology therapeutics during a conference call at 1:30 p.m. PT (4:30 p.m. ET). Rain focuses on developing therapies targeting oncogenic drivers through a tumor-agnostic strategy, with its lead candidate milademetan (RAIN-32) being an oral MDM2 inhibitor. Investors can access a recorded version of the call on the company’s website for 30 days.
- Upcoming conference call on November 10, 2021, to discuss financial results and recent advancements.
- Focus on precision oncology, potentially enhancing market position.
- Lead product candidate milademetan (RAIN-32) targets oncogenic drivers, offering a strategic advantage.
- None.
NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the third quarter that ended September 30, 2021 and highlights of recent progress, on Wednesday, November 10, 2021. On that day, management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the Company’s business and financial results.
Conference Call and Webcast Details:
Date: November 10, 2021
Time: 1:30 p.m. PT (4:30 p.m. ET)
Dial In Numbers: 1 (833) 562-0127 (U.S. Toll Free) / 1 (661) 567-1105 (U.S. Toll)
Passcode: 1985710
Webcast Link: https://edge.media-server.com/mmc/p/6qek8226
The call will be recorded and available for replay on the Company’s website for approximately 30 days after the call.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan (RAIN-32), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Media Contact:
Jordyn Temperato
LifeSci Communications
+1.646.876.5196
jtemperato@lifescicomms.com
FAQ
When will Rain Therapeutics release its Q3 financial results?
What time is the conference call for Rain Therapeutics?
What is the lead product candidate of Rain Therapeutics?
How can I access the recorded conference call by Rain Therapeutics?
